FDA Brief

Warning letters Food

FDA warning letter to

GeroNova Research Inc.

MediumIssued Nov 18, 2021Posted Jan 18, 2022Office of Human and Animal Food Operations - West Division 5

FDA warned GeroNova Research that disease claims on its Amazon store and social media make its carnitine and R-lipoic acid supplements unapproved, misbranded drugs.

What happened

FDA reviewed GeroNova's Amazon.com store and its Facebook and Twitter pages from September to October 2021; the social media pages send consumers to the company website, which sends them to Amazon to buy. FDA quoted posts and product pages linking carnitine and R-lipoic acid to diabetes, depression, Parkinson's disease, liver disease, heart disease and neuropathy. Because the products are marketed for treating disease, FDA treats them as drugs, not supplements.

What FDA found

  1. The company's website and social media posts claim the products diagnose, treat, cure or prevent disease, which legally makes them drugs.

    Section 201(g)(1)(B) of the Act [21 U.S.C. § 321(g)(1)(B)]
  2. The products are not generally recognized as safe and effective for these uses, so they are "new drugs" and were sold without FDA approval.

    Sections 301(d) and 505(a) of the Act [21 U.S.C. § 331(d) and 355(a)]
  3. The products carry no adequate directions for use, because the diseases they are pitched for cannot be safely self-treated without a licensed practitioner.

    Section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]; 21 CFR 201.5
  4. Selling these misbranded drugs across state lines violates the Act.

    Section 301(a) of the Act [21 U.S.C. § 331(a)]

What FDA wants

FDA asks the company to write back within 15 working days describing the specific steps taken to fix the violations and prevent them from recurring, with supporting documents. If corrections cannot be finished in that time, the company must explain the delay and give a completion date.

Who should pay attention

  • supplement brands that make health claims on Amazon listings
  • companies whose social media posts link to product sales pages
  • marketing and regulatory reviewers for dietary supplement sellers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk